Targeting multidrug resistance in cancer
The DOI matches its Crossref record; 267 of the 267 references it cites were found in a registry or an index.
Abstract
Effective treatment of metastatic cancers usually requires the use of toxic chemotherapy. In most cases, multiple drugs are used, as resistance to single agents occurs almost universally. For this reason, elucidation of mechanisms that confer simultaneous resistance to different drugs with different targets and chemical structures - multidrug resistance - has been a major goal of cancer biologists during the past 35 years. Here, we review the most common of these mechanisms, one that relies on drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters. We describe various approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by ABC transporters.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ROS also play an important role in multidrug resistance.”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [56]
Citations
Cites
1 retracted
Chang, G., & Roth, C. B. (2001) · Science · doi:10.1126/science.293.5536.1793 · Cited by 619
RetractedLipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536 · cited 1×
“Significance of ABC transporters in cancer Much has been learned about ABC transporters since MDR was first describe”
BackgroundSelf-citationABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985 · cited 1×
“The ABC transporter family ABC transporters, named after their distinctive ATP-binding cassette domains, are conserved proteins that typically translocate solutes across cellular membrane”
BackgroundTumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668 · cited 1×
“According to the cancer stem cell model, this population of drug-resistant pluripotent cells defies treatment and serves as an unrestricted reservoir for drug-resistant tumour relaps”
BackgroundA surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., et al. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.11.757 · Cited by 3,289
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Thiebaut, F., Tsuruo, T., Hamada, H., Gottesman, M. M., Pastan, I., & Willingham, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.21.7735 · Cited by 2,777
Self-citationA multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322
Research works printed but not linked: 2
- van der Holt, B. et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106, 2646–2654 (2005). · DOI · Paper page
- Joly, F. J. C. et al. A phase 3 study of PSC 833 in combination with paclitaxel and carboplatin (PC-PSC) versus paclitaxel and carboplatin (PC) alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary cancer of the peritoneum. Proc. Am. Soc. Clin. Oncol. 21, Abstract 806 (2002).
Cited by
Items 601–700 of 1,013
Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer
Yang, Z., Su, W., Zhang, Q., Niu, L., Feng, B., Zhang, Y. L., Huang, F., He, J., Zhou, Q., Zhou, X., et al. (2025) · Advanced Science · doi:10.1002/advs.202408845 · Cited by 146
Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells
Cai, J., Damaraju, V. L., Groulx, N., Mowles, D., Peng, Y., Robins, M. J., Cass, C. E., & Gros, P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5528 · Cited by 93
Hanke, U., May, K., Rozehnal, V., Nagel, S., Siegmund, W., & Weitschies, W. (2010) · European journal of pharmaceutics and biopharmaceutics · doi:10.1016/j.ejpb.2010.06.008 · Cited by 93
Liu, X., Tee, H.-W., & Go, M. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.10.006 · Cited by 95
Kiss, K., Brozik, A., Kucsma, N., Toth, A., Gera, M., Berry, L., Vallentin, A., Vial, H., Vidal, M., & Szakacs, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037378 · Cited by 93
“Accordingly, several ABC transporters act as ‘‘multidrug resistance’’ (MDR) proteins that provide resistance against chemotherapy in cancer [24].”
BackgroundSelf-citationPajic, M., Iyer, J. K., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Jonkers, J., Borst, P., & Rottenberg, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0041 · Cited by 94
“One of the best-characterized mechanisms of multidrug resistance in vitro is drug efflux by ATP-binding cassette (ABC) transporters such as ABCB1/MDR1/P-glycoprotein (P-gp), ABCG2/ BCRP, or ABCC1/MRP1 (3).”
BackgroundZheng, W., Yin, T., Chen, Q., Qin, X., Huang, X., Zhao, S., Xu, T., Chen, L., & Liu, J. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.11.041 · Cited by 97
The emerging role of microRNAs in resistance to lung cancer treatments
MacDonagh, L., Gray, S. G., Finn, S. P., Cuffe, S. D., O'Byrne, K. J., & Barr, M. P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.009 · Cited by 103
Bypassing Multidrug Resistance in Cancer Cells with Biodegradable Polymer Capsules
Yan, Y., Ochs, C. J., Such, G. K., Heath, J. K., Nice, E. C., & Caruso, F. (2010) · Advanced Materials · doi:10.1002/adma.201003162 · Cited by 94
Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant
Sharma, A. K., Zhang, L., Li, S., Kelly, D. L., Alakhov, V. Y., Batrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.07.031 · Cited by 92
“The key mechanisms of development of MDR in cancer cells include decreased uptake of drugs in cells, alteration of cellular targets that reduce the capacity of cytotoxic drugs to kill the cells and increased energy-dependent efflux of drugs that can enter the cells by diffusion through the plasma membrane [18].”
BackgroundInvestigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2)
Juvale, K., Gallus, J., & Wiese, M. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.10.007 · Cited by 92
Vitexin induces apoptosis by suppressing autophagy in multi-drug resistant colorectal cancer cells
Bhardwaj, M., Cho, H. J., Paul, S., Jakhar, R., Khan, I., Lee, S., Kim, B. Y., Krishnan, M., Khaket, T. P., Lee, H. G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22890 · Cited by 94
“High level expression of ABC proteins is observed in various human cancers and results in development of resistance to multiple anti-cancer drugs [4].”
BackgroundNatarajan, K., Bhullar, J., Shukla, S., Burcu, M., Chen, Z., Ambudkar, S. V., & Baer, M. R. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.12.006 · Cited by 92
Zhao, X.-Q., Xie, J., Chen, X.-G., Sim, H. M., Zhang, X., Liang, Y.-J., Singh, S., Talele, T. T., Sun, Y.-L., Ambudkar, S. V., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076299 · Cited by 97
“In general, the “first-generation” P-gp inhibitors, including verapamil, quinine, and cyclosporine, were ineffective or toxic at the doses required to attenuate P-gp function in vivo (Szakács et al., 2006).”
BackgroundTomao, F., Papa, A., Rossi, L., Strudel, M., Vici, P., Lo Russo, G., & Tomao, S. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-48 · Cited by 92
“These contribute to tumor resistance by actively transporting drugs across cell membranes through ATP hydrolysis [83,124-127].”
BackgroundTargeted Drug Delivery Systems Mediated by a Novel Peptide in Breast Cancer Therapy and Imaging
Lu, R., Chen, M., Chang, D.-K., Chiu, C., Lin, W.-C., Yan, S.-L., Wang, Y., Kuo, Y., Yeh, C.-Y., Lo, A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066128 · Cited by 93
“These defects often lead to incomplete tumor response, multiple drug resistance, and ultimately, therapeutic failure [11].”
BackgroundSen, R., Natarajan, K., Bhullar, J., Shukla, S., Fang, H.-B., Cai, L., Chen, Z., Ambudkar, S. V., & Baer, M. R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0302 · Cited by 93
“The ATP-binding cassette (ABC) transport proteins ABCB1 [P-glycoprotein (Pgp), MDR1], ABCC1 [multidrug resistance protein-1 (MRP1)] and ABCG2 [breast cancer resistance protein (BCRP), mitoxantrone resistance protein (MXR)] are strongly implicated in MDR (1).”
BackgroundInfluentialHu, F., Yuan, Y., Mao, D., Wu, W., & Liu, B. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.08.018 · Cited by 92
Yuan, Y., Kwok, R. T. K., Zhang, R., Tang, B. Z., & Liu, B. (2014) · Chem. Commun. · doi:10.1039/c4cc05255b · Cited by 91
Xu, Y., Ohms, S., Li, Z., Wang, Q., Gong, G., Hu, Y., Mao, Z., Shannon, M. F., & Fan, J. Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082062 · Cited by 98
“transmembrane proteins, play pivotal roles in this process [2].”
BackgroundH6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo
Yang, Y., Guan, D., Lei, L., Lu, J., Liu, J. Q., Yang, G., Yan, C., Zhai, R., Tian, J., Bi, Y., et al. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.01.015 · Cited by 91
“, 2012), which could pump out “toxic substrates”, such as paclitaxel and vinblastine, to reduce the drug-mediated cytotoxicity (Szakacs et al., 2006; Sharom, 2014; Kathawala et al., 2015).”
Chang, L., Hu, Z., Zhou, Z., & Zhang, H. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491659 · Cited by 91
Drug–drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1)
Aszalós, A. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.07.021 · Cited by 93
Influence of Melanosome Dynamics on Melanoma Drug Sensitivity
Chen, K. G., Leapman, R. D., Zhang, G., Lai, B., Valencia, J. C., Cardarelli, C. O., Vieira, W. D., Hearing, V. J., & Gottesman, M. M. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp259 · Cited by 90
Self-citationNuclear Factor (Erythroid-Derived 2)-Like 2 Regulates Drug Resistance in Pancreatic Cancer Cells
Hong, Y. B., Kang, H. J., Kwon, S. Y., Kim, H. J., Kwon, K. Y., Cho, C. H., Lee, J.-M., Kallakury, B. V. S., & Bae, I. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181c31314 · Cited by 91
Wang, Z., Wang, N., Li, W., Liu, P., Chen, Q., Situ, H., Zhong, S., Guo, L., Lin, Y. H., Shen, J., et al. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu155 · Cited by 91
“However, the current therapeutic strategies are seldom successful in reversing drug resistance in clinical settings (3).”
BackgroundThe ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo
Heffeter, P., Atil, B., Kryeziu, K., Groza, D., Koellensperger, G., Körner, W., Jungwirth, U., Mohr, T. T., Keppler, B. K., & Berger, W. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.05.018 · Cited by 92
“Sorafenib as well as sunitinib have been recently reported to inhibit several ATP-binding cassette (ABC) transporters,(10,24) which are responsible for multidrug resistance due to enhanced efflux of diverse drugs including doxorubicin, etoposide, taxol or imatinib.(25) In addi-”
BackgroundJeddi, F., Soozangar, N., Sadeghi, M. R., Somi, M. H., & Samadi, N. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.03.008 · Cited by 92
A Transformable Chimeric Peptide for Cell Encapsulation to Overcome Multidrug Resistance
Zhang, C., Liu, L., Qiu, W., Zhang, Y., Song, W., Zhang, L., Wang, S., & Zhang, X. (2018) · Small · doi:10.1002/smll.201703321 · Cited by 90
Guo, W., Chen, Z., Feng, X., Shen, G., Huang, H., Liang, Y., Zhao, B., Li, G., & Hu, Y. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00874-9 · Cited by 93
“Considering P-gp is a transmembrane glycoprotein with a molecular weight of 170 KD and works as an energy-dependent "drug pump", they could bind to ATP, acquire energy to pump intracellular drugs out of the cell, reduce the drug concentration in the cell and result in drug resistance [53, 54].”
RetractedInhibition of NPC1L1 disrupts adaptive responses of drug‐tolerant persister cells to chemotherapy
Zhang, Z., Qin, S., Chen, Y., Zhou, L., Yang, M. X., Tang, Y., Zuo, J., Zhang, J., Mizokami, A., Nice, E. C., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114903 · Cited by 97
Zhao, P., Yin, S., Qiu, Y., Sun, C., & Yu, H. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02217-2 · Cited by 117
Therapeutic Agents Triggering Nonapoptotic Cancer Cell Death
Kornienko, A., Mathieu, V., Rastogi, S. K., Lefranc, F., & Robert Kiss, A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400136m · Cited by 95
Romagnoli, R., Baraldi, P. G., Salvador, M. K., Preti, D., Tabrizi, M. A., Bassetto, M., Brancale, A., Hamel, E., Castagliuolo, I., Bortolozzi, R., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400043d · Cited by 92
ATP-Binding Cassette C Transporters in Human Pancreatic Carcinoma Cell Lines
Hagmann, W., Jesnowski, R., Faissner, R., Guo, C., & Löhr, M. J. (2008) · Pancreatology · doi:10.1159/000178884 · Cited by 106
Particle Carriers for Combating Multidrug-Resistant Cancer
Yan, Y., Björnmalm, M., & Caruso, F. (2013) · ACS Nano · doi:10.1021/nn405632s · Cited by 89
“This phenomenon is commonly referred to as the multidrug resistance (MDR) of cancer.(3) The development of MDR contributes to significant treatment failure in patients with metastatic cancer.”
BackgroundResistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.
Geretto, M., Pulliero, A., Rosano, C., Zhabayeva, D., Bersimbaev, R. I., & Izzotti, A. (2017) · PubMed Central · Cited by 108
Tremlett, W. D. J., Goodman, D. M., Steel, T. R., Kumar, S., Wieczorek, A., Walsh, F. P., Sullivan, M. P., Hanif, M., & Hartinger, C. G. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.213950 · Cited by 94
Wang, Z., Ma, R., Yan, L., Chen, X., & Zhu, G. (2015) · Chemical Communications · doi:10.1039/c5cc04376j · Cited by 88
Deka, S. R., Quarta, A., Corato, R. D., Riedinger, A., Cingolani, R., & Pellegrino, T. (2010) · Nanoscale · doi:10.1039/c0nr00570c · Cited by 93
ABCB5 expression and cancer stem cell hypothesis in oral squamous cell carcinoma
Grimm, M. R., Krimmel, M., Polligkeit, J., Alexander, D., Munz, A., Kluba, S., Keutel, C., Hoffmann, J., Reinert, S., & Hoefert, S. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.027 · Cited by 89
Zhou, Y., Hu, Y., Yang, M., Jat, P., Li, K., Lombardo, Y., Xiong, D., Coombes, R. C., Raguz, S., & Yagüe, E. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.167 · Cited by 95
“of drug-induced DNA damage or the induction of drugdetoxification enzymes.(3) In addition, the acquisition of the epithelial–mesenchymal transition (EMT)-like phenotype of cancer cells and cancer stem cells (CSCs) also have critical roles in drug resistance.”
BackgroundDavis, B. M., Jensen, R. O., Williams, P. M., & O’Shea, P. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013522 · Cited by 89
“In addition, as MDR poses a significant problem for the treatment of conditions including cancer, the search for potential inhibitors has been intensive [45,46,47].”
BackgroundMunuganti, R. S. N., Leblanc, E., Axerio-Cilies, P., Labriere, C., Frewin, K., Singh, K., Hassona, M. D. H., Lack, N. A., Li, H., Ban, F., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm3015712 · Cited by 88
Pramanik, D., Campbell, N. R., Das, S., Gupta, S., Chenna, V., Bisht, S., Sysa‐Shah, P., Bedja, D., Karikari, C. A., Steenbergen, C., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.543 · Cited by 96
“Current approaches to overcome MDR include a focus on drug discovery, with, in many cases, an end goal of combination therapy [2].”
InfluentialZhang, J., Xu, Y., Gao, Y., Chen, C., Zheng, Z.-S., Yun, M., Weng, H.-W., Xie, D., & Ye, S. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0586-y · Cited by 90
RetractedRecent Advances in Multicellular Tumor Spheroid Generation for Drug Screening
Lee, K.-H., & Kim, T. P. (2021) · Biosensors · doi:10.3390/bios11110445 · Cited by 102
“As a result of this crosstalk, tumorigenesis and responses to multidrug resistance are linked [7,8].”
BackgroundZattoni, I. F., Delabio, L. C., Dutra, J. D. P., Kita, D. H., Scheiffer, G., Hembecker, M., Pereira, G. D. S., Moure, V. R., & Valdameri, G. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114346 · Cited by 95
A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer
Bu, H., He, X., Zhang, Z., Yin, Q., Yu, H., & Li, Y. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.05.039 · Cited by 91
Wong, I. L. K., Chan, K., Tsang, K. H., Lam, C. Y., Zhao, Y., Chan, T. H., & Chow, L. M. C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900194w · Cited by 102
Fu, P., Kong, F., Li, X., Wang, Y., & Zhu, W. (2014) · Organic Letters · doi:10.1021/ol501523d · Cited by 95
Tumor metabolism, cancer cell transporters, and microenvironmental resistance
Alfarouk, K. O. (2016) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2016.1140753 · Cited by 86
Total Synthesis and Biological Evaluation of Natural and Designed Tubulysins
Nicolaou, K. C., Yin, J., Mandal, D., Erande, R. D., Klahn, P., Jin, M., Aujay, M. A., Sandoval, J., Gavrilyuk, J. I., & Vourloumis, D. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b12557 · Cited by 95
Ozcelikkale, A., Moon, H., Linnes, M., & Han, B. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1460 · Cited by 87
Kim, Y. H., Ishii, G., Goto, K., Ota, S., Kubota, K., Murata, Y., Mishima, M., Saijo, N., Nishiwaki, Y., & Ochiai, A. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.10.008 · Cited by 87
“cytotoxic drugs commonly used in the treatment of SCLC, including etoposide, irinotecan, and topotecan(4).”
In vivo methods for imaging blood–brain barrier function and dysfunction
Harris, W. J., Asselin, M., Hinz, R., Parkes, L. M., Allan, S. M., Schießl, I., Boutin, H., & Dickie, B. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05997-1 · Cited by 98
Multilayer Spheroids To Quantify Drug Uptake and Diffusion in 3D
Achilli, T.-M., McCalla, S., Meyer, J., Tripathi, A., & Morgan, J. R. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500002y · Cited by 91
Markers predicting clinical benefit in breast cancer from microtubule-targeting agents
Pusztai, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm534 · Cited by 88
Song, X., Wen, Y., Zhu, J., Zhao, F., Zhang, Z., & Li, J. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b01344 · Cited by 87
Diaryl ether derivatives as anticancer agents – a review
Bedos‐Belval, F., Rouch, A., Vanucci‐Bacqué, C., & Baltas, M. (2012) · MedChemComm · doi:10.1039/c2md20199b · Cited by 94
Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen
Michaelis, M., Agha, B., Rothweiler, F., Löschmann, N., Voges, Y., Mittelbronn, M., Starzetz, T., Harter, P. N., Abhari, B. A., Fulda, S., et al. (2015) · Scientific Reports · doi:10.1038/srep08202 · Cited by 85
Peptidomimetics as a new generation of antimicrobial agents: current progress
Méndez‐Samperio, P. (2014) · Infection and Drug Resistance · doi:10.2147/idr.s49229 · Cited by 92
“79 At present, some radiolabeled γ -AApeptides have been used as tracers for positron emission tomography, indicating a therapeutic application as anticancer agents.”
BackgroundMeena, A. S., Sharma, A., Kumari, R., V, Mohammad, N., Singh, S. V., & Bhat, M. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061524 · Cited by 85
“Great deal of work has been done to know the mechanisms, especially, on P-gp towards the development of resistance in cancer cells [27,28].”
BackgroundBai, F., Wang, C., Lu, Q., Zhao, M., Ban, F., Yu, D., Guan, Y., Luan, X., Liu, Y., Chen, H., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.062 · Cited by 86
“However, no benefit and/or even serious toxicity occurred and ultimately led to the failure of phase III clinical trials [2,26]; the main reasons involved are relative to the unfavorable pharmacological properties and toxicity of the chemosensitive agents, as well as the severely adverse interaction between the chemo-…”
Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling
Wang, W., Wang, L., Mizokami, A., Shi, J., Zou, C., Dai, J., Keller, E. T., Lü, Y., & Zhang, J. (2017) · 癌症:英文版 · doi:10.1186/s40880-017-0203-x · Cited by 85
“However, multidrug resistance remains a key challenge for the success of chemotherapy [7, 8].”
BackgroundTackling drug resistance with efflux pump inhibitors: from bacteria to cancerous cells
Christena, L. R., Subramaniapillai, S. G., Ulaganathan, V., & Nagarajan, S. (2019) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2019.1607248 · Cited by 93
“…lines exhibit increased expression of ABC transporters, especially ABCB1, ABCC1 and ABCG2, and many chemotherapeutic agents are substrates for these three transporters, mammalian ABC transport inhibition are considered as attractive therapeutic targets (Szak acs et al. 2006; Teodori et al. 2006).”
BackgroundRecent advances in immunotherapy, immunoadjuvant, and nanomaterial-based combination immunotherapy
Zhou, B., Liu, J., Lin, M., Zhu, J., & Chen, W. R. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214009 · Cited by 88
Ying, X., Chen, Q., Yang, Y., Wu, Z., Zeng, W., Miao, C., Huang, Q., & Ai, K. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02186-6 · Cited by 94
Overcoming drug resistance by regulating nuclear receptors
Chen, T. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.008 · Cited by 88
Chen, Y., Bieber, M. M., & Teng, N. N. H. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22015 · Cited by 84
“Currently, there are 48 members of the ABC transporter family have been identified in humans [2].”
BackgroundTopotecan Central Nervous System Penetration Is Altered by a Tyrosine Kinase Inhibitor
Zhuang, Y., Fraga, C. H., Hubbard, K. E., Hagedorn, N. L., Panetta, J. C., Waters, C. M., & Stewart, C. F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0929 · Cited by 85
“Finally, we found that Bcrp1 was expressed on the apical aspect of the choroid plexus of FVB mice, which, coupled with the orientation of transporters expressed at the blood-brain barrier ( 39 ), would explain the differential effect of the tyrosine kinase inhibitor modulator on topotecan brain penetration.”
BackgroundOvercoming Multidrug Resistance in Human Cancer Cells by Natural Compounds
Nabekura, T. (2010) · Toxins · doi:10.3390/toxins2061207 · Cited by 92
Sherman‐Baust, C. A., Becker, K. G., Wood, W. H., Zhang, Y., & Morin, P. J. (2011) · Journal of Ovarian Research · doi:10.1186/1757-2215-4-21 · Cited by 94
“On the other hand, paclitaxel and doxorubicin are known substrates for the ATP-dependent efflux pump P-glycoprotein (MDR transporter system, ABCB1) and up-regulation of MDR1 has been associated with clinical drug resistance in multiple systems [23].”
BackgroundMapping the functional yeast ABC transporter interactome
Snider, J., Hanif, A., Lee, M. E., Jin, K., Yu, A. R., Graham, C., Chuk, M., Damjanovic, D., Wierzbicka, M., Tang, P., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1293 · Cited by 84
miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2
QIU, T., ZHOU, L., WANG, T., XU, J., WANG, J., CHEN, W., ZHOU, X., HUANG, Z., ZHU, W., SHU, Y., et al. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1439 · Cited by 85
“…detoxification of anticancer drugs by the glutathione system, a defective apoptotic pathway, enhanced DNA repair or increased tolerance to DNA damage, decreased uptake of water-soluble drugs and enhanced drug efflux from cancer cells mediated by ATP-binding cassette (ABC) transporters (1-4).”
Multifunctional Electrospun Nanofibers for Enhancing Localized Cancer Treatment
Fu, Y., Li, X., Ren, Z., Mao, C., & Han, G. (2018) · Small · doi:10.1002/smll.201801183 · Cited by 84
Yang, Q., Wang, C., Lang, L., Zhou, Y., Wang, H., & Shang, D. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0112-8 · Cited by 84
“Moreover, conventional cancer therapies fail to eliminate all tumor cells due to intrinsic or acquired drug resistance, which is the most common cause of tumor recurrence (Szakács et al. 2006).”
BackgroundChao, P., Deshmukh, M., Kutscher, H. L., Gao, D., Rajan, S. S., Hu, P., Laskin, D. L., Stein, S., & Sinko, P. J. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328332a322 · Cited by 84
“In addition, higher localized drug concentration also helps to prevent the development of multidrug resistance in cancer cells [3, 4].”
Supramolecular Drug Delivery Systems Based on Water-Soluble Pillar[n]arenes
Wu, X., Gao, L., Hu, X., & Wang, L. (2016) · The Chemical Record · doi:10.1002/tcr.201500265 · Cited by 83
Ferrous ions doped calcium carbonate nanoparticles potentiate chemotherapy by inducing ferroptosis
Han, Y., Dong, Z., Wang, C., Li, Q., Hao, Y., Yang, Z., Zhu, W., Zhang, Y., Liu, Z., & Feng, L. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.002 · Cited by 85
Wei, Z., Yuan, S., Hao, J., & Fang, X. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.09.014 · Cited by 88
Kweon, S. H., Song, J. H., & Kim, T. S. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.147 · Cited by 92
Russo, R. I. C., García, M. G., Alaniz, L. D., Blanco, G. A. C., Álvarez, É., & Hajos, S. E. (2007) · International Journal of Cancer · doi:10.1002/ijc.23122 · Cited by 88
“Nowadays research is focused on the ‘‘fourth generation’’ inhibitors among old drugs, such as disulfiram or herbal components, which have been shown to modulate Pgp in vitro and could be used in safety doses in vivo.(3)”
BackgroundChen, M., Huang, S., Zhang, X., Zhang, B., Zhu, H., Yang, V. W., & Zou, X. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24122 · Cited by 87
“Although MDR have several causes, one major form of resistance to chemotherapy has been correlated with three molecular “pumps” including P-glycoprotein (P-gp), multidrug resistant protein1 (MRP1), and breast cancer resistance protein (BCRP) [Szakacs et al., 2006].”
Molecular–functional imaging of cancer: to image and imagine
Glunde, K., Pathak, A. P., & Bhujwalla, Z. M. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.05.002 · Cited by 97
Breaking Bad: the Structure and Function of the Blood-Brain Barrier in Epilepsy
Han, H., Mann, A., Ekstein, D., & Eyal, S. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0096-2 · Cited by 83
“Previously, P-gp inhibitors have been investigated for their ability to reverse multidrug resistance of tumors (139).”
BackgroundChen, G., Ma, B., Wang, Y., Xie, R., Li, C., Dou, K., & Gong, S. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b14083 · Cited by 87
Synthetically lethal nanoparticles for treatment of endometrial cancer
Ebeid, K., Meng, X., Thiel, K. W., Do, A., Geary, S. M., Morris, A. S., Pham, E. L., Wongrakpanich, A., Chhonker, Y. S., Murry, D. J., et al. (2017) · Nature Nanotechnology · doi:10.1038/s41565-017-0009-7 · Cited by 86
Deng, Y., Käfer, F. H., Chen, T., Jin, Q., Ji, J., & Agarwal, S. (2018) · Small · doi:10.1002/smll.201802420 · Cited by 82
Zhou, Y., Zhou, Y., Yang, M., Wang, K., Liu, Y., Mingda, Z., Yang, Y., Jin, C.-Y., Wang, R., & Hu, R. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101131 · Cited by 83
Wang, Z., Zhan, Y., Xu, J., Wang, Y., Sun, M., Chen, J., Liang, T., Wu, L., & Xu, K. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c00107 · Cited by 80
Structural Basis of Drug Recognition by the Multidrug Transporter ABCG2
Kowal, J., Ni, D., Jackson, S. M., Manolaridis, I., Stahlberg, H., & Locher, K. P. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.166980 · Cited by 84
Chua, C. L., Zaiden, N., Chong, K.-H., See, S.-J., Wong, M. C., Ang, B.-T., & Tang, C. (2008) · Journal of neurosurgery · doi:10.3171/jns/2008/109/11/0856 · Cited by 85
Aroui, S., Ram, N., Appaix, F., Ronjat, M., Kénani, A., Pirollet, F., & WAARD, M. M. D. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9782-1 · Cited by 82
“Unfortunately, resistance to this agent is common and thereby the development of new drugs or alternative drug delivery systems to overcome the unsuccessful outcome of patients treatment is desirable (18,19).”
BackgroundLiu, J., Li, Q., Zhang, J., Huang, L., Qi, C., Xu, L., Liu, X., Wang, G., Wang, L., & Wang, Z. (2016) · Small · doi:10.1002/smll.201602567 · Cited by 82
Hikichi, Y., Honda, K., Hikami, K., Miyashita, H., Kaieda, I., Murai, S., Uchiyama, N., Hasegawa, M., Kawamoto, T., Sato, T., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0762 · Cited by 81
“anaphylaxis (13), and the potential for tumors to become refractory or resistant due to multidrug resistance (6).”
BackgroundmiR-181b/Notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC
Wang, X., Meng, Q., Qiao, W., Ma, R., Ju, W., Hu, J., Lu, H., Cui, J., Jin, Z. H., Zhao, Y., et al. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1072-1 · Cited by 81
Barakat, A., Islam, M. S., Ghawas, H. M., Al‐Majid, A. M., El‐Senduny, F. F., Badria, F. A.-E., Elshaier, Y. A. M. M., & Ghabbour, H. A. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.01.053 · Cited by 85
“These cells are relatively resistant to therapy and are able to effect cancer cell repopulation in vivo after cytotoxic drug treatments have ended [2].”
BackgroundLi, X., Zhao, Y., Zhang, T., & Xing, D. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001240 · Cited by 84
Gel Formulations for Topical Treatment of Skin Cancer: A Review
Slavkova, M., Tzankov, B., Popova, T., & Voycheva, C. (2023) · Gels · doi:10.3390/gels9050352 · Cited by 96
Metadata
- Authors
- Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M.
- Affiliations
- Institute of Molecular Life Sciences (HU)
- National Institutes of Health (US)
- Corresponding author
- Gottesman, Michael M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 219-234
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2055904567
- Cited by
- 3,609
- References
- 265
- Citations by year
- 2026: 62 · 2025: 119 · 2024: 149 · 2023: 196 · 2022: 172 · 2021: 210 · 2020: 226 · 2019: 194 · 2018: 234 · 2017: 228 · 2016: 246 · 2015: 247 · 2014: 232 · 2013: 230 · 2012: 199
- FWCI
- 11.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- multidrug resistance, ABC transporters, drug efflux, chemoresistance, ABC transporter inhibitors, cancer chemotherapy
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.